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Abstract
Cholangiocarcinoma arises from the epithelial lining of the biliary tree. It 
accounts for approximately 3% of all gastrointestinal malignancies. This chap-
ter looks at the new advances that have been made in the management of distal 
cholangiocarcinoma, based on a literature review. Diagnosis of the disease resides 
mainly in clinical presentation and radiological diagnosis and biopsy indicated in 
selected cases. Surgical resection is the main curative treatment for distal cholan-
giocarcinoma, and resectability of the tumor can now be assessed using multiple 
radiological imaging studies. Resection margins and lymph node invasion status 
are the two important prognostic factors after surgery. Pancreaticoduodenectomy 
is the standard surgical treatment of choice in distal cholangiocarcinoma; however, 
combined major vascular and hepatopancreaticoduodenectomy can be indicated 
in selected cases. Adjuvant therapy is clearly indicated after surgical resection with 
survival improvement, but optimal adjuvant treatment strategy has not yet been 
established.
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1. Introduction
Cholangiocarcinoma arises from the epithelial lining of the biliary tree. Given 
the biliary tree anatomical differences and diversity, biliary tree cancers are most 
commonly classified according to their location into intrahepatic and extrahepatic 
cholangiocarcinomas, which are further classified into perihilar and distal type. 
Over all, these malignancies account for approximately 3% of all gastrointesti-
nal malignancies [1]. Perihilar cholangiocarcinoma accounts for 50% of them, 
followed by distal cholangiocarcinoma (40%), and the remainder is intrahepatic 
disease [2].
Cholangiocarcinoma can also be classified based on its macroscopic growth pat-
tern into three types: mass-forming exophytic type, periductal infiltrative type, or 
intraductal polypoid type. For distal cholangiocarcinoma, the periductal infiltrative 
type is the most common macroscopic growth pattern identified [3].
2. Staging and survival
Over all, biliary malignancies have poor prognosis. Surgical resection is the 
mainstay of treatment and it is possible only for localized disease without distant 
spread. The resection rate of bile duct cancer is different based on its location, and 
distal bile duct cancer has the highest respectability rate among other types [4]. In 
distal bile duct cancer, patients usually manifest jaundice early in the disease course 
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and likely seek medical care prior to metastasis development. Lymph node involve-
ment, perineural invasion, lymphatic invasion, vascular invasion, and pancreatic 
invasion in addition to tumor depth of invasion are important prognostic factors 
and correlated with survival [5–8]. However, achieving negative resection margins 
is proposed to be the single most important predictor of survival [8]. The 8th AJCC 
UICC 2017 categorized cholangiocarcinoma based on its location in intrahepatic, 
Primary tumor (T)
T category T criteria
TX Primary tumor cannot be assessed
Tis Carcinoma in situ/high-grade dysplasia
T1 Tumor invades the bile duct wall with a depth less than 5 mm
T2 Tumor invades the bile duct wall with a depth of 5–12 mm
T3 Tumor invades the bile duct wall with a depth greater than 12 mm
T4 Tumor involves the celiac axis, superior mesenteric artery, and/or common 
hepatic artery
Regional lymph nodes (N)
N category N criteria
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in one to three regional lymph nodes
N2 Metastasis in four or more regional lymph nodes
Distant metastasis (M)
M category M criteria
M0 No distant metastasis
M1 Distant metastasis
Prognostic stage groups
When T is… And N is… And M is… Then the stage group is…
Tis N0 M0 0
T1 N0 M0 I
T1 N1 M0 IIA
T1 N2 M0 IIIA
T2 N0 M0 IIA
T2 N1 M0 IIB
T2 N2 M0 IIIA
T3 N0 M0 IIB
T3 N1 M0 IIB
T3 N2 M0 IIIA
T4 N0 M0 IIIB
T4 N1 M0 IIIB
T4 N2 M0 IIIB
Any T Any N M1 IV
Table 1. 
Distal bile duct cancer TNM staging AJCC UICC 2017 [12].
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hilar, and distal type and provided separate staging system for each one. The 
recent changes in distal CBD cancer designated the T level according to the depth 
of invasion rather than invaded structures, and N stage would include the number 
of involved lymph nodes rather than being involved or not. N1 will be given for 
involvement of 1–3 lymph nodes and N2 for the involvement of 4 and more lymph 
nodes Table 1. These changes improved the survival stratification between the 
stages based on the TNM stage [9, 10]. The overall 5-year survival of stages I, II, and 
III was 59.0, 35.4, and 14.7%, respectively [10].
3. Clinical presentation and diagnosis
The typical presentation of distal cholangiocarcinoma is painless jaundice in 
patients in the 5th–7th decade of life, while 10% of patients will have cholangitis 
as their initial presentation. A total of 56% of patients will present with constitu-
tional symptom of malignancy like anorexia, fatigue, and weight loss [11]. Serum 
biochemical testing will show cholestatic jaundice pattern with elevated alkaline 
phosphatase, gamma-glutamyl transpeptidase and bilirubin levels. CA 19-9 is a 
tumor marker used in the workup of bile duct cancer. It has low sensitivity and 
specificity for cholangiocarcinoma, and it can also be elevated in biliary obstruction 
of benign disease. CA 19-9 seems to be correlated with prognosis and stage of the 
disease [12, 13], but its role as a diagnostic test is limited.
Cross sectional, enhanced contrast imaging is essential diagnostic modality in 
patients with distal cholangiocarcinoma, and it should be obtained before biliary 
intervention since its accuracy will be diminished after stent as a result of decom-
pression, image artifact, or as consequence of local complication to the biliary 
intervention [14, 15]. Cholangiocarcinoma may be seen as stricture (Figure 1) in 
periductal infiltrative type or mass forming lesion in intraductal polypoid type or 
exophytic type. High resolution CT can identify biliary dilatation, tumor extent, 
and its relationship with the vascular system and adjacent organ, anatomical varia-
tion, lymphadenopathy, and distant metastasis. Periductal infiltrative type may 
manifest as thickened bile duct wall, which is often seen on CT as hypoattenuated 
on portovenous and hyperattenuated on delayed phase [16, 17]. Magnetic resonance 
imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is a 
noninvasive modality that is competent to provide cholangiography for assessing 
the extent of bile duct extension and considered the preferred imaging for the 
diagnosis of suspected cholangiocarcinoma. Utilizing the high soft tissue contrasts 
and multiplanar capability, it is better at detecting infiltrative ductal tumor and its 
Figure 1. 
Distal cholangiocarcinoma. Images showing narrowing segment in distal common bile duct (stricture) (arrow) 
with proximal biliary dilatation in coronal T2-weighted image (a), MRCP (b), and ERCP (c) [20].
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local extent of tumor, biliary anatomy, invasion to surrounding structure, and liver 
metastasis. However, it is inferior to high resolution CT for vascular involvement 
and distant metastasis [18–21].Infiltrating periductal cholangiocarcinoma can be 
identified on MRI as irregular wall thickening of bile duct, with proximal biliary 
dilatation, which enhances gradually to peak on delayed image, while intraductal 
polypoid type is typically identified as enhancing intraductal mass with proximal 
biliary dilation [22, 23]. MRCP is an essential noninvasive cholangiography to 
evaluate the longitudinal tumor extension in the bile duct proximal and distal to the 
obstruction and provides valuable preoperative biliary mapping [24]. It has higher 
sensitivity, specificity, and accuracy in differentiating benign from malignant bili-
ary obstruction compared to ERCP [24].
Cholangiocarcinoma can be evaluated also by direct cholangiography with endo-
scopic retrograde cholangiopancreatography (ERCP) (Figure 1) or percutaneous 
transhepatic cholangiography (PTC), which typically present as dominant stricture 
or filling defect. They can delineate biliary anatomy and determine the level of bile 
duct involvement, which will help to identify resectability and surgical planning. It 
also allows for bile sampling for brush cytology and relives the biliary obstruction. 
The diagnostic yield of cytology has a low sensitivity of 42% but a high specificity 
of 98% and a positive predictive value of 98% of patients who had cancers [25]. The 
sensitivity of brush cytology can be improved further more to 46–68% by using 
fluorescence in situ hybridization (FISH) to detect cancerous epithelial cells  
[26, 27]. EUS is an important diagnostic tool in the evaluation of distal biliary 
obstruction because it is very specific in predicting unresectability [28], and it is 
challenging some time to differentiate distal cholangiocarcinoma from other peri-
ampullary tumors based on other diagnostic modality. It helps to assess the extrahe-
patic biliary system, regional lymph node, and local extension to adjacent structure 
[24, 29]. It can also detect small lesions that were missed by another modality [28]. 
The sensitivity and specificity of EUS in detecting malignant biliary stricture are 
reported to be, in meta-analysis, 78 and 84%, respectively [30]. EUS also facilitates 
FNA cytology assessment which will increase the diagnostic yield of EUS. Recent 
meta-analysis found that EUS-FNA has a sensitivity of 80% and a specificity of 97% 
for diagnosing malignant biliary stricture [31].
The diagnostic algorithm is controversial in the literature, and it depends 
on institutional availability and experience of different diagnostic modali-
ties. However, a general concept in evaluating distal cholangiocarcinoma is to 
determine tumor resectability, by assessing local extension of the tumor and its 
relationship with adjacent organs including vascular structure and presence of 
distant metastasis, and biliary tree mapping to assess longitudinal tumor exten-
sion. Cross-sectional, enhanced contrast imaging with MRI and/or CT with 
MRCP is the preferred diagnostic modality [32, 33] for assessing bile duct cancer. 
Direct cholangiography with ERCP/PTC is necessary in unresectable patients or 
in patients who need therapeutic intervention [33]. For patients with resectable 
disease, preoperative pathological diagnosis in not necessary [32, 33], especially 
in highly suspicious cases of malignant biliary obstruction, since diagnostic yield 
of preoperative tissue biopsy is low and cannot rule out malignancy. In patients 
with unresectable disease or when the diagnosis is not clear, then, biopsy is 
indicated. Serum IgG4 should also be considered if diagnosis is not clear because 
IgG4-associated cholangitis may present with jaundice and stricture, mimicking 
cholangiocarcinoma [33]. Preoperative biliary drainage is definitely indicated 
in patients with acute cholangitis or if patients will have delayed surgery for 
preoperative optimization [15, 24]. Preoperative routine drainage is not preferred 
owing to increased postoperative complication with no added benefit compared 
to no drainage [34, 35].
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4. Surgical treatment
Surgical resection with curative intent is the only cure for distal cholangiocar-
cinoma. In most cases, pancreaticoduodenectomy is the surgical procedure for 
periampullary tumors, including distal cholangiocarcinoma. The goal of curative 
resection is to resect the tumor and regional lymph node with negative resection 
margin [36, 37]. Achieving a precise review of imaging to assess local extension 
of the tumor, lymph node, proximal ductal involvement, and presence of distant 
metastasis is an essential step in surgical planning to reach to the best outcome. 
The presence of peritoneal or distant metastasis (lung, liver, bone, or paraaortic 
lymph node) considered a contraindication for surgery [38, 39]. En-bloc major 
vascular resection may be necessary to achieve complete oncologic resection and 
does not preclude curative resection. Portal vein and/or hepatic artery resection and 
reconstruction are indicated if the tumor is locally advanced and invading them. 
Pancreaticoduodenectomy combined with vascular resection is reported to be a 
feasible technique with acceptable mortality, morbidity, and survival benefit [40].
Lymph node metastasis is an independent predictor for poor survival in distal 
cholangiocarcinoma [41]. Adequate lymphadenectomy for regional lymph node 
is important for complete oncologic resection, staging purpose, and planning of 
postoperative adjuvant therapy. Regional lymph node of distal bile duct is defined 
to be the lymph node along the porta hepatis, hepatic artery, anterior and posterior 
to the head of pancreas, and the lymph node along superior mesenteric artery [42].
Resection margin status of bile duct is highly correlated with survival in chol-
angiocarcinoma. Adequate assessment of the biliary system before any surgical 
planning is a critical step to achieve negative resection margin. Identification of the 
proximal extent of the disease helps to define the level of proximal resection and 
identify the patients who need a more extensive procedure to undergo preoperative 
optimization. Patients who have extensive periductal infiltration into the intrahe-
patic biliary duct may benefit from hepatopancreaticoduodenectomy (HPD) and 
should not be precluded from curative resection [33]. It is considered aggressive 
surgical resection for extrahepatic cholangiocarcinoma; however, with the improve-
ment in surgical techniques and perioperative care, the postoperative mortality 
improved, compared to early experience, and it demonstrated favorable survival 
once the negative resection margin was achieved [43]. This procedure may be justi-
fied in well-selected and prepared patients, which may include perioperative biliary 
drainage and portal vein embolization to augment future liver remnant hypertro-
phy, with advanced cholangiocarcinoma [44]. Intraoperative frozen section of the 
proximal duct margin is required to assess margin status, and further re-resection 
is indicated when it is feasible to achieve negative resection margin. However, 
sometimes, the frozen section is repeatedly positive and no more extrahepatic bile 
duct to be excised, which conveys a challenging situation. If the frozen section 
report is carcinoma in situ, then no resection is required because it has comparable 
oncologic outcome with negative resection margin [45, 46], but if the frozen section 
is positive for invasive cancer, then unplanned hepatopancreaticoduodenectomy 
(HPD) may be indicated in selected cases. Minor or major central liver resection 
in this situation can help to achieve negative resection margin and preserve func-
tional liver parenchyma, especially in those patients who are not well prepared for 
major hepatectomy, with no decreased long-term survival been reported in hilar 
cholangiocarcinoma literature. Left hepatectomy can also be an option in cases with 
left hepatic duct only involvement, because it reserves more future liver remnant 
in comparison to right hepatectomy or trisegmentectomy [47, 48]. However, it is 
a comorbid procedure, and risks and benefits should critically be evaluated and 
balanced before attempting liver resection in this situation.
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After curative resection, the risk of recurrence dictates the need for additional 
treatment modality to improve disease-free and overall survival. The role of adjuvant 
therapy in cholangiocarcinoma is not yet agreed on because most of these stud-
ies combine different types of hepatobiliary cancers and nonrandomized studies. 
However, the available data, including randomized trial, showed survival benefit 
and suggested that chemotherapy can decrease the risk of distant recurrences while 
radiotherapy or chemoradiation can reduce the risk of local recurrence [49]. This sur-
vival benefit is clearly observed in patients with lymph node positive and/or margin 
positive although an optimal adjuvant treatment strategy has not yet been established 
[32, 33]. The suggested treatment options by NCCN guidelines are fluoropyrimidine-
based or gemcitabine-based chemotherapy or fluoropyrimidine chemoradiation 
followed by additional fluoropyrimidine or gemcitabine chemotherapy [33].
5. Advanced cholangiocarcinoma
Advanced distal cholangiocarcinoma, including locally advanced or metastatic, 
has overall poor prognosis. Most of them have obstructive jaundice due to biliary 
obstruction and they may also experience pruritus, pain, or cholangitis. Therefore, 
they are in need for palliative therapy to relieve their symptom, improve survival, 
and have a better quality of life.
Biliary drainage is indicated to relieve the symptom of biliary obstruction which 
will improve their quality of life and prepare some of those patients for chemo-
therapy. It can be obtained nonsurgically via endoscopic biliary drainage (EBD) or 
percutaneous transhepatic biliary drainage (PTBD). There is no difference between 
the two approaches in therapeutic success rate, overall complication, and 30 days 
mortality; however, PTBD has lower incidence of cholangitis [50, 51]. In regard to 
stent type, metallic stent is found to be better than plastic stent because it provides 
longer stent patency and lower risk of recurrent obstruction [52]. The classical way 
of biliary drainage is the surgical bypass with biliary-enteric anastomosis. Surgical 
bypass provides excellent relive of jaundice with low mortality and morbidity 
[53–55]. A meta-analysis of endoscopic versus surgical bypass in malignant biliary 
obstruction revealed no differences between surgical bypass and endoscopic plastic 
stents in the rates of technical success, therapeutic success, survival, and quality of 
life; however, the risk of all complication was in favor of plastic stent, and recurrent 
biliary obstruction was in favor of surgical bypass. But, the lower risk of biliary 
obstruction in surgical bypass is likely to result also in metallic stent. Therefore, 
nonsurgical stenting is the preferred first choice in malignant biliary obstruction 
in patients with short life expectancy. Surgical bypass can be considered in patients 
found to be unresectable during attempted curative resection and in patients with 
expected prolonged survival [4, 54, 56].
Systemic chemotherapy has proven to prolong the survival of advanced chol-
angiocarcinoma compared with best supportive care, with cisplatin/gemcitabine 
combination as a standard of care. Chemoradiation is another treatment strategy used 
for advanced cholangiocarcinoma, which provides effective local control and may 
prolong survival; however, it is recommended to patients with locally advanced dis-
ease without distant metastasis [33]. Photodynamic therapy is another local ablative 
technique that uses laser therapy to destruct bile duct cell cancer that has absorbed 
photosensitizing agent either through percutaneous transhepatic cholangiography or 
with ERC. It yields a good result in terms of increased survival benefit, improvement 
in biliary drainage, and better quality of life compared to biliary stent only [57, 58].
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